- Title: Subtitle
- A Randomized, Placebo (PBO) Controlled, Double-Blind P2b Trial of GC4419 (Avisopasem Manganese) to Reduce Severe Radiation-Related Oral Mucositis (SOM) in Patients (pts) with Locally Advanced Squamous Cell Cancer of the Oral Cavity (OC) or Oropharynx (OP)
- Creators
- C.M. Anderson - University of IowaC. Lee - Cancer Care NorthwestD. Saunders - Northeast Cancer Center/Health Sciences North, Sudbury, ON, CanadaA. Curtis - Spartanburg Regional Medical CenterN.E. Dunlap - University of Louisville Hospital, Department of Radiation Oncology, Louisville, KYC. Nangia - UC/Irvine Medical Center, Orange, CAA. Lee - HOPE Cancer Center of East Texas, Tyler, TXJ. Holmlund - Galera Therapeutics, Inc., Malvern, PAJ. Brill - Galera Therapeutics, Inc., Malvern, PAS.T. Sonis - BioModels, Boston, MAJ. Buatti - University of Iowa
- Resource Type
- Abstract
- Publication Details
- International journal of radiation oncology, biology, physics, Vol.102(3), pp.S109-S109
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.ijrobp.2018.06.276
- ISSN
- 0360-3016
- eISSN
- 1879-355X
- Language
- English
- Date published
- 11/01/2018
- Academic Unit
- Neurosurgery; Pharmacy Practice and Science; Otolaryngology; Radiation Oncology
- Record Identifier
- 9984304978302771
Abstract
A Randomized, Placebo (PBO) Controlled, Double-Blind P2b Trial of GC4419 (Avisopasem Manganese) to Reduce Severe Radiation-Related Oral Mucositis (SOM) in Patients (pts) with Locally Advanced Squamous Cell Cancer of the Oral Cavity (OC) or Oropharynx (OP)
International journal of radiation oncology, biology, physics, Vol.102(3), pp.S109-S109
11/01/2018
DOI: 10.1016/j.ijrobp.2018.06.276
Details
Metrics
8 Record Views